▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Unity Biotechnology (NASDAQ: UBX)

$0.37

(-51.9%)

-$0.40

Price as of June 30, 2025, 3:57 p.m. ET

Unity Biotechnology Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
UBX	-71.55%	-99.54%	-65.92%	-100%
S&P	+13.63%	+99.14%	+14.77%	+136%

Unity Biotechnology Company Info

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

News & Analysis

Featured Article

Here's Why Unity Biotechnology Is Getting Crushed Today

The development-stage biopharma announced disappointing results from a clinical trial.

Maxx Chatsko | Aug 17, 2020

Featured Article

Unity Biotech: Buy at the Low?

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

Maxx Chatsko | Aug 22, 2019

Here's Why Unity Biotechnology Dropped as Much as 20.4% Today

Maxx Chatsko | Jun 18, 2019

The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services